APP and Alzheimer disease: Table 2 lists important inflammasome inhibitors in clinical trials as potential therapeutics for Alzheimer’s disease (AD). Dapansutrile (OLT1177), a selective NLRP3 inhibitor has completed a Phase II trial for gout (NCT02104050) [77]. In APP/PS1 AD mouse models, Dapansutrile reduced neuroinflammation by decreasing IL-1β and microglial activation, leading to a lower Aβ plaque burden [78].